{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T20:01:20Z","timestamp":1794513680454,"version":"4.9.1"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008871","name":"Juvenile Diabetes Research Foundation United States of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000901","name":"Juvenile Diabetes Research Foundation International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.atherosclerosis.2024.118615","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T02:25:09Z","timestamp":1727231109000},"page":"118615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["The dual role of lipids in chronic kidney disease: Pathogenic culprits and therapeutic allies"],"prefix":"10.1016","volume":"398","author":[{"given":"Elena","family":"Giardini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Sadlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Godson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4908-5474","authenticated-orcid":false,"given":"Eoin","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4s","key":"10.1016\/j.atherosclerosis.2024.118615_bib1","first-page":"S117","article-title":"Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.118615_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S2213-8587(14)70065-8","article-title":"Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease","volume":"2","author":"de Vries","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.118615_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/nu11040722","article-title":"Lipid accumulation and chronic kidney disease","volume":"11","author":"Gai","year":"2019","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.118615_bib4","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.kint.2017.09.033","article-title":"Renal tubule injury: a driving force toward chronic kidney disease","volume":"93","author":"Liu","year":"2018","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.118615_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41581-019-0248-y","article-title":"Targeting the progression of chronic kidney disease","volume":"16","author":"Ruiz-Ortega","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.118615_bib6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.118615_bib7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.atherosclerosis.2024.118615_bib8","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.118615_bib9","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.118615_bib10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2024.118615_bib11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.118615_bib12","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.118615_bib13","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.118615_bib14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1053\/j.ajkd.2020.03.023","article-title":"NSAIDs in CKD: are they safe?","volume":"76","author":"Baker","year":"2020","journal-title":"Am. J. Kidney Dis."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.118615_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2337\/db08-1328","article-title":"Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy","volume":"58","author":"Berthier","year":"2009","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.118615_bib16","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1053\/j.ajkd.2015.06.028","article-title":"Cholesterol metabolism in CKD","volume":"66","author":"Reiss","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib17","first-page":"8","article-title":"Lipid disorders in patients with renal failure: role in cardiovascular events and progression of chronic kidney disease","volume":"6","author":"Visconti","year":"2016","journal-title":"J Clin Transl Endocrinol"},{"issue":"8311","key":"10.1016\/j.atherosclerosis.2024.118615_bib18","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(82)91513-6","article-title":"Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease","volume":"2","author":"Moorhead","year":"1982","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.118615_bib19","doi-asserted-by":"crossref","first-page":"755","DOI":"10.34067\/KID.0006152020","article-title":"Podocyte lipotoxicity in CKD","volume":"2","author":"Kim","year":"2021","journal-title":"Kidney"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2024.118615_bib20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41581-023-00741-w","article-title":"Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease","volume":"19","author":"Mitrofanova","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2024.118615_bib21","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1681\/ASN.2007010089","article-title":"Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet","volume":"18","author":"Kume","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.118615_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072632","article-title":"Lipotoxicity and diabetic nephropathy: novel mechanistic insights and therapeutic opportunities","volume":"21","author":"Opazo-R\u00edos","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.118615_bib23","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/ki.2011.58","article-title":"The glomerular endothelial cell coat is essential for glomerular filtration","volume":"79","author":"Friden","year":"2011","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.118615_bib24","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1681\/ASN.2017060627","article-title":"The adiponectin receptor agonist AdipoRon ameliorates diabetic nephropathy in a model of type 2 diabetes","volume":"29","author":"Kim","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"issue":"51","key":"10.1016\/j.atherosclerosis.2024.118615_bib25","doi-asserted-by":"crossref","first-page":"26487","DOI":"10.1074\/jbc.M116.730564","article-title":"Exendin-4 ameliorates lipotoxicity-induced glomerular endothelial cell injury by improving ABC transporter A1-mediated cholesterol efflux in diabetic apoE knockout mice","volume":"291","author":"Yin","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155377","article-title":"ABCA1 deficiency-mediated glomerular cholesterol accumulation exacerbates glomerular endothelial injury and dysfunction in diabetic kidney disease","volume":"139","author":"Zhang","year":"2023","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.118615_bib27","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.kint.2016.06.013","article-title":"Protection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury","volume":"90","author":"Szeto","year":"2016","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.118615_bib28","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.kint.2016.06.013","article-title":"Protection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury","volume":"90","author":"Szeto","year":"2016","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118615_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.apsb.2020.07.002","article-title":"VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses","volume":"11","author":"Shen","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.118615_bib30","doi-asserted-by":"crossref","first-page":"F821","DOI":"10.1152\/ajprenal.00196.2010","article-title":"Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids","volume":"299","author":"Sieber","year":"2010","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118615_bib31","doi-asserted-by":"crossref","first-page":"F118","DOI":"10.1152\/ajprenal.00110.2008","article-title":"Structural and functional changes in the kidneys of high-fat diet-induced obese mice","volume":"296","author":"Deji","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.118615_bib32","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.2337\/db13-0399","article-title":"Cyclodextrin protects podocytes in diabetic kidney disease","volume":"62","author":"Merscher-Gomez","year":"2013","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.118615_bib33","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1194\/jlr.P040501","article-title":"Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy","volume":"55","author":"Herman-Edelstein","year":"2014","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118615_bib34","doi-asserted-by":"crossref","DOI":"10.1515\/med-2024-0918","article-title":"CD36-mediated podocyte lipotoxicity promotes foot process effacement","volume":"19","author":"Hua","year":"2024","journal-title":"Open Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.118615_bib35","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/ki.2015.121","article-title":"Smad3 deficiency protects mice from obesity-induced podocyte injury that precedes insulin resistance","volume":"88","author":"Sun","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2840-4-2","article-title":"Saturated free fatty acids and apoptosis in microvascular mesangial cells: palmitate activates pro-apoptotic signaling involving caspase 9 and mitochondrial release of endonuclease G","volume":"4","author":"Mishra","year":"2005","journal-title":"Cardiovasc. Diabetol."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.118615_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071421","article-title":"Lipotoxicity-induced PRMT1 exacerbates mesangial cell apoptosis via endoplasmic reticulum stress","volume":"18","author":"Park","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.118615_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.pharep.2018.12.008","article-title":"Astragaloside IV inhibits palmitate-mediated oxidative stress and fibrosis in human glomerular mesangial cells via downregulation of CD36 expression","volume":"71","author":"Su","year":"2019","journal-title":"Pharmacol. Rep."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.118615_bib39","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1523-1755.2002.kid578.x","article-title":"IGF-1-induced lipid accumulation impairs mesangial cell migration and contractile function","volume":"62","author":"Berfield","year":"2002","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118615_bib40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3762","article-title":"Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development","volume":"21","author":"Kang","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib41","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1414070","article-title":"High glucose promotes CD36 expression by upregulating peroxisome proliferator-activated receptor \u03b3 levels to exacerbate lipid deposition in renal tubular cells","volume":"2017","author":"Feng","year":"2017","journal-title":"BioMed Res. Int."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.118615_bib42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.kint.2018.09.023","article-title":"ATF6\u03b1 downregulation of PPAR\u03b1 promotes lipotoxicity-induced tubulointerstitial fibrosis","volume":"95","author":"Jao","year":"2019","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118615_bib43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41419-022-04515-3","article-title":"STAT6 contributes to renal fibrosis by modulating PPAR\u03b1-mediated tubular fatty acid oxidation","volume":"13","author":"Li","year":"2022","journal-title":"Cell Death Dis."},{"issue":"9784","key":"10.1016\/j.atherosclerosis.2024.118615_bib44","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.118615_bib45","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014840","article-title":"Statins and all-cause mortality in patients undergoing hemodialysis","volume":"9","author":"Jung","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118615_bib46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1021\/acsptsci.9b00075","article-title":"New advances in targeting the resolution of inflammation: implications for specialized pro-resolving mediator GPCR drug discovery","volume":"3","author":"Park","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib47","article-title":"The atlas of inflammation resolution (AIR)","author":"Serhan","year":"2020","journal-title":"Mol. Aspect. Med."},{"issue":"7146","key":"10.1016\/j.atherosclerosis.2024.118615_bib48","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nature05877","article-title":"Resolvin E1 and protectin D1 activate inflammation-resolution programmes","volume":"447","author":"Schwab","year":"2007","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.atherosclerosis.2024.118615_bib49","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1182\/blood-2012-04-423525","article-title":"Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators","volume":"120","author":"Dalli","year":"2012","journal-title":"Blood"},{"issue":"50","key":"10.1016\/j.atherosclerosis.2024.118615_bib50","doi-asserted-by":"crossref","first-page":"38376","DOI":"10.1074\/jbc.M605146200","article-title":"Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages","volume":"281","author":"Freire-de-Lima","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"4819","key":"10.1016\/j.atherosclerosis.2024.118615_bib51","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1126\/science.2820055","article-title":"Leukotrienes and lipoxins: structures, biosynthesis, and biological effects","volume":"237","author":"Samuelsson","year":"1987","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.118615_bib52","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1073\/pnas.83.7.1983","article-title":"On the stereochemistry and biosynthesis of lipoxin B","volume":"83","author":"Serhan","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"35","key":"10.1016\/j.atherosclerosis.2024.118615_bib53","doi-asserted-by":"crossref","first-page":"16340","DOI":"10.1016\/S0021-9258(18)66571-8","article-title":"Stereochemistry and biosynthesis","volume":"261","author":"Serhan","year":"1986","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.118615_bib54","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1172\/JCI114503","article-title":"Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro","volume":"85","author":"Serhan","year":"1990","journal-title":"J. Clin. Invest."},{"issue":"7503","key":"10.1016\/j.atherosclerosis.2024.118615_bib55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib56","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1100\/tsw.2010.113","article-title":"Lipoxin and aspirin-triggered lipoxins","volume":"10","author":"Romano","year":"2010","journal-title":"Sci. World J."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.118615_bib57","doi-asserted-by":"crossref","first-page":"C870","DOI":"10.1152\/ajpcell.1999.277.5.C870","article-title":"Hepatocytes are a rich source of novel aspirin-triggered 15-epi-lipoxin A(4)","volume":"277","author":"Titos","year":"1999","journal-title":"Am. J. Physiol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.118615_bib58","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1073\/pnas.0907342107","article-title":"Resolvin D1 binds human phagocytes with evidence for proresolving receptors","volume":"107","author":"Krishnamoorthy","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.118615_bib59","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1096\/fj.10-159913","article-title":"FPR2\/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis","volume":"24","author":"Maderna","year":"2010","journal-title":"Faseb. J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118615_bib60","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41467-020-14728-9","article-title":"Structure of formylpeptide receptor 2-Gi complex reveals insights into ligand recognition and signaling","volume":"11","author":"Zhuang","year":"2020","journal-title":"Nat. Commun."},{"issue":"45","key":"10.1016\/j.atherosclerosis.2024.118615_bib61","doi-asserted-by":"crossref","first-page":"18232","DOI":"10.1073\/pnas.1308253110","article-title":"Ligand-specific conformational change of the G-protein-coupled receptor ALX\/FPR2 determines proresolving functional responses","volume":"110","author":"Cooray","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"52","key":"10.1016\/j.atherosclerosis.2024.118615_bib62","doi-asserted-by":"crossref","first-page":"18685","DOI":"10.1073\/pnas.1410938111","article-title":"Nonredundant protective properties of FPR2\/ALX in polymicrobial murine sepsis","volume":"111","author":"Gobbetti","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"10.1016\/j.atherosclerosis.2024.118615_bib63","first-page":"1817","article-title":"Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation","volume":"16","author":"McMahon","year":"2002","journal-title":"Faseb. J."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.118615_bib64","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.4049\/jimmunol.0803175","article-title":"Lipoxin A4: anti-inflammatory and anti-angiogenic impact on endothelial cells","volume":"182","author":"Baker","year":"2009","journal-title":"J. Immunol."},{"issue":"21","key":"10.1016\/j.atherosclerosis.2024.118615_bib65","doi-asserted-by":"crossref","first-page":"15606","DOI":"10.1074\/jbc.M611004200","article-title":"The Lipoxin A4 receptor is coupled to SHP-2 activation: implications for regulation of receptor tyrosine kinases","volume":"282","author":"Mitchell","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.118615_bib66","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.4049\/jimmunol.0903526","article-title":"Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation","volume":"184","author":"Dufton","year":"2010","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2024.118615_bib67","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1097\/01.ASN.0000032417.73640.72","article-title":"Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo","volume":"13","author":"Mitchell","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.118615_bib68","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.4049\/jimmunol.164.4.1663","article-title":"Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived Macrophages1","volume":"164","author":"Godson","year":"2000","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.118615_bib69","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1681\/ASN.2012060550","article-title":"Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGF\u03b2R1","volume":"24","author":"Brennan","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.118615_bib70","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.4049\/jimmunol.156.6.2264","article-title":"Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells","volume":"156","author":"Papayianni","year":"1996","journal-title":"J. Immunol."},{"issue":"20","key":"10.1016\/j.atherosclerosis.2024.118615_bib71","doi-asserted-by":"crossref","first-page":"13266","DOI":"10.1073\/pnas.202296999","article-title":"Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes","volume":"99","author":"J\u00f3zsef","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.118615_bib72","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00011-024-01885-6","article-title":"A signaling network map of Lipoxin (LXA4): an anti-inflammatory molecule","volume":"73","author":"Suchitha","year":"2024","journal-title":"Inflamm. Res."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.118615_bib73","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1523\/JNEUROSCI.5529-08.2009","article-title":"Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke","volume":"29","author":"Sobrado","year":"2009","journal-title":"J. Neurosci."},{"issue":"40","key":"10.1016\/j.atherosclerosis.2024.118615_bib74","doi-asserted-by":"crossref","first-page":"14530","DOI":"10.1073\/pnas.1410851111","article-title":"Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway","volume":"111","author":"Fredman","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.118615_bib75","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1084\/jem.20042031","article-title":"Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1","volume":"201","author":"Arita","year":"2005","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.118615_bib76","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/jm501051x","article-title":"FPR2\/ALXR agonists and the resolution of inflammation","volume":"58","author":"Corminboeuf","year":"2015","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.118615_bib77","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.2337\/db16-1405","article-title":"Protective effect of let-7 miRNA family in regulating inflammation in diabetes-associated atherosclerosis","volume":"66","author":"Brennan","year":"2017","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.118615_bib78","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1681\/ASN.2012060550","article-title":"Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFbetaR1","volume":"24","author":"Brennan","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.118615_bib79","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1096\/fj.201600952R","article-title":"Lipoxin A4 stimulates endothelial miR-126-5p expression and its transfer via microvesicles","volume":"31","author":"Codagnone","year":"2017","journal-title":"Faseb. J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118615_bib80","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.20081880","article-title":"Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions","volume":"206","author":"Serhan","year":"2008","journal-title":"J. Exp. Med."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2024.118615_bib81","doi-asserted-by":"crossref","first-page":"14677","DOI":"10.1074\/jbc.M300218200","article-title":"Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells: autacoids in anti-inflammation","volume":"278","author":"Hong","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.118615_bib82","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.20020760","article-title":"Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals","volume":"196","author":"Serhan","year":"2002","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.118615_bib83","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1161\/ATVBAHA.112.249508","article-title":"Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions","volume":"32","author":"Norling","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.118615_bib84","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1084\/jem.20150225","article-title":"Identification of resolvin D2 receptor mediating resolution of infections and organ protection","volume":"212","author":"Chiang","year":"2015","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.118615_bib85","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.4049\/jimmunol.1502268","article-title":"Resolvin D3 is dysregulated in arthritis and reduces arthritic inflammation","volume":"197","author":"Arnardottir","year":"2016","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118615_bib86","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41420-021-00708-5","article-title":"RvD1 accelerates the resolution of inflammation by promoting apoptosis of the recruited macrophages via the ALX\/FasL-FasR\/caspase-3 signaling pathway","volume":"7","author":"Xiang","year":"2021","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.118615_bib87","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.1502522","article-title":"Signaling and immunoresolving actions of resolvin D1 in inflamed human visceral adipose tissue","volume":"197","author":"Titos","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1091753","article-title":"Resolvin D1\/N-formyl peptide receptor 2 ameliorates paclitaxel-induced neuropathic pain through the activation of IL-10\/Nrf2\/HO-1 pathway in mice","volume":"14","author":"Su","year":"2023","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.118615_bib89","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood.2022019145","article-title":"Infectious neutrophil deployment is regulated by resolvin D4","volume":"142","author":"Libreros","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.118615_bib90","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1084\/jem.192.8.1197","article-title":"Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing","volume":"192","author":"Serhan","year":"2000","journal-title":"J. Exp. Med."},{"issue":"21","key":"10.1016\/j.atherosclerosis.2024.118615_bib91","doi-asserted-by":"crossref","first-page":"7671","DOI":"10.1073\/pnas.0409271102","article-title":"Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis","volume":"102","author":"Arita","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.118615_bib92","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI42545","article-title":"Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation","volume":"121","author":"Oh","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"4 Pt 1","key":"10.1016\/j.atherosclerosis.2024.118615_bib93","first-page":"643","article-title":"Anti-microinflammatory lipid signals generated from dietary N-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions","volume":"51","author":"Serhan","year":"2000","journal-title":"J. Physiol. Pharmacol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.118615_bib94","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.chembiol.2006.09.011","article-title":"Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis","volume":"13","author":"Tjonahen","year":"2006","journal-title":"Chem. Biol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.118615_bib95","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.4049\/jimmunol.1103652","article-title":"Resolvin E2 formation and impact in inflammation resolution","volume":"188","author":"Oh","year":"2012","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.118615_bib96","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.4049\/jimmunol.178.6.3912","article-title":"Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation","volume":"178","author":"Arita","year":"2007","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118615_bib97","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ibd.21029","article-title":"Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis","volume":"16","author":"Ishida","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.118615_bib98","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1096\/fj.13-227728","article-title":"The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype","volume":"27","author":"Dalli","year":"2013","journal-title":"Faseb. J."},{"issue":"46","key":"10.1016\/j.atherosclerosis.2024.118615_bib99","doi-asserted-by":"crossref","first-page":"16526","DOI":"10.1073\/pnas.1407123111","article-title":"Maresin 1 biosynthesis during platelet-neutrophil interactions is organ-protective","volume":"111","author":"Abdulnour","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.118615_bib100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149319","article-title":"Identification and actions of a novel third maresin conjugate in tissue regeneration: mctr3","volume":"11","author":"Dalli","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.118615_bib101","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1172\/JCI129448","article-title":"Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions","volume":"129","author":"Chiang","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.118615_bib102","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173537","article-title":"Satellite glial GPR37L1 and its ligand maresin 1 regulate potassium channel signaling and pain homeostasis","volume":"134","author":"Bang","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.118615_bib103","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1172\/JCI124219","article-title":"A maresin 1\/RORalpha\/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis","volume":"129","author":"Han","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101749","article-title":"Maresin 1 activates brown adipose tissue and promotes browning of white adipose tissue in mice","volume":"74","author":"Laiglesia","year":"2023","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106018","article-title":"Maresin 1 alleviates dextran sulfate sodium-induced ulcerative colitis by regulating NRF2 and TLR4\/NF-kB signaling pathway","volume":"78","author":"Qiu","year":"2020","journal-title":"Int. Immunopharm."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.118615_bib106","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1080\/03008207.2020.1780218","article-title":"Maresin-1 suppresses IL-1beta-induced MMP-13 secretion by activating the PI3K\/AKT pathway and inhibiting the NF-kappaB pathway in synovioblasts of an osteoarthritis rat model with treadmill exercise","volume":"62","author":"Lu","year":"2021","journal-title":"Connect. Tissue Res."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.118615_bib107","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1161\/CIRCRESAHA.116.309492","article-title":"Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice","volume":"119","author":"Viola","year":"2016","journal-title":"Circ. Res."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2024.118615_bib108","doi-asserted-by":"crossref","first-page":"14677","DOI":"10.1074\/jbc.M300218200","article-title":"Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation","volume":"278","author":"Hong","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib109","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3389\/fphar.2018.01582","article-title":"The protectin family of specialized pro-resolving mediators: potent immunoresolvents enabling innovative approaches to target obesity and diabetes","volume":"9","author":"Hansen","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.118615_bib110","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.chembiol.2011.06.008","article-title":"Novel proresolving aspirin-triggered DHA pathway","volume":"18","author":"Serhan","year":"2011","journal-title":"Chem. Biol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.118615_bib111","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.4049\/jimmunol.176.3.1848","article-title":"Anti-inflammatory actions of neuroprotectin D1\/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes","volume":"176","author":"Serhan","year":"2006","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.118615_bib112","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1172\/JCI99888","article-title":"GPR37 regulates macrophage phagocytosis and resolution of inflammatory pain","volume":"128","author":"Bang","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.118615_bib113","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1096\/fj.14-268441","article-title":"Novel proresolving and tissue-regenerative resolvin and protectin sulfido-conjugated pathways","volume":"29","author":"Dalli","year":"2015","journal-title":"Faseb. J."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.118615_bib114","doi-asserted-by":"crossref","first-page":"5902","DOI":"10.4049\/jimmunol.177.9.5902","article-title":"Resolvin D series and protectin D1 mitigate acute kidney injury","volume":"177","author":"Duffield","year":"2006","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.118615_bib115","first-page":"3130","article-title":"n-3 Docosapentaenoic acid-derived protectin D1 promotes resolution of neuroinflammation and arrests epileptogenesis","volume":"141","author":"Frigerio","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110167","article-title":"LXA4 protected mice from renal ischemia\/reperfusion injury by promoting IRG1\/Nrf2 and IRAK-M-TRAF6 signal pathways","volume":"261","author":"Tie","year":"2024","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.118615_bib117","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1046\/j.1523-1755.2003.00106.x","article-title":"Modification of the transcriptomic response to renal ischemia\/reperfusion injury by lipoxin analog","volume":"64","author":"Kieran","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110139","article-title":"Dose-dependent ameliorating effect of lipoxin A4 on gentamicin-induced nephrotoxicity in rats: the role of TNFalpha, TGF-beta, ICAM-1, and JNK signaling","volume":"366","author":"Ibrahim","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib119","article-title":"Lipoxin A4 restores septic renal function via blocking crosstalk between inflammation and premature senescence","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.118615_bib120","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1096\/fj.11-185017","article-title":"Lipoxin A(4) and benzo-lipoxin A(4) attenuate experimental renal fibrosis","volume":"25","author":"Borgeson","year":"2011","journal-title":"Faseb. J."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.118615_bib121","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cmet.2015.05.003","article-title":"Lipoxin A4 attenuates obesity-induced adipose inflammation and associated liver and kidney disease","volume":"22","author":"Borgeson","year":"2015","journal-title":"Cell Metabol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.118615_bib122","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.2337\/db17-1317","article-title":"Lipoxins protect against inflammation in diabetes-associated atherosclerosis","volume":"67","author":"Brennan","year":"2018","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.118615_bib123","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2017101112","article-title":"Lipoxins regulate the early growth response-1 network and reverse diabetic kidney disease","volume":"29","author":"Brennan","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.118615_bib124","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41581-021-00454-y","article-title":"Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function","volume":"17","author":"Brennan","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109170","article-title":"LipoxinA(4) analog BML-111 protects podocytes cultured in high-glucose medium against oxidative injury via activating Nrf2 pathway","volume":"111","author":"Hao","year":"2022","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib126","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.plefa.2017.08.009","article-title":"Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients","volume":"125","author":"Goicoechea","year":"2017","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib127","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fphys.2020.00285","article-title":"Resolvin D1 protects against ischemia\/reperfusion-induced acute kidney injury by increasing Treg percentages via the ALX\/FPR2 pathway","volume":"11","author":"Luan","year":"2020","journal-title":"Front. Physiol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.118615_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e12269","article-title":"Resolvin D1 attenuates sepsis induced acute kidney injury targeting mitochondria and NF-kappaB signaling pathway","volume":"8","author":"Wang","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib129","article-title":"RvD1 attenuated susceptibility to ischemic AKI in diabetes by downregulating nuclear factor-kappa B signal and inhibiting apoptosis","volume":"12","author":"Li","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib130","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.intimp.2018.12.029","article-title":"Effects of AT-RvD1 on paraquat-induced acute renal injury in mice","volume":"67","author":"Hu","year":"2019","journal-title":"Int. Immunopharm."},{"issue":"21","key":"10.1016\/j.atherosclerosis.2024.118615_bib131","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111634","article-title":"ATRvD1 attenuates renal tubulointerstitial injury induced by albumin overload in sepsis-surviving mice","volume":"22","author":"Silva","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.118615_bib132","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/path.4050","article-title":"Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation","volume":"228","author":"Qu","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.782660","article-title":"Maresin 1 attenuates lipopolysaccharide-induced acute kidney injury via inhibiting NOX4\/ROS\/NF-kappaB pathway","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib134","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2147\/JIR.S442729","article-title":"Maresin-1 attenuates sepsis-associated acute kidney injury via suppressing inflammation, endoplasmic reticulum stress and pyroptosis by activating the AMPK\/SIRT3 pathway","volume":"17","author":"Sun","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib135","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3389\/fphar.2019.01323","article-title":"Maresin 1 mitigates sepsis-associated acute kidney injury in mice via inhibition of the NF-kappaB\/STAT3\/MAPK pathways","volume":"10","author":"Sun","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2024.118615_bib136","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.838782","article-title":"Formation, signaling and occurrence of specialized pro-resolving lipid mediators-what is the evidence so far?","volume":"13","author":"Schebb","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.118615_bib137","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/jbm.a.37512","article-title":"Sustained release resolvin D1 liposomes are effective in the treatment of osteoarthritis in obese mice","volume":"111","author":"Dravid","year":"2023","journal-title":"J. Biomed. Mater. Res."},{"issue":"275","key":"10.1016\/j.atherosclerosis.2024.118615_bib138","doi-asserted-by":"crossref","first-page":"275ra20","DOI":"10.1126\/scitranslmed.aaa1065","article-title":"Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice","volume":"7","author":"Fredman","year":"2015","journal-title":"Sci. Transl. Med."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024011870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024011870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:39:14Z","timestamp":1779305954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915024011870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":138,"alternative-id":["S0021915024011870"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.118615","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The dual role of lipids in chronic kidney disease: Pathogenic culprits and therapeutic allies","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.118615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"118615"}}